Anterior Segment of EyeAxial LengthBiometrics Measurement
Investigational drug(s) / intervention(s)
UNITY DXANTERION
UNITY DX: Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties
ANTERION: Commercially available non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties
Study summary
The purpose of this study is to compare the measurements obtained with two different biometers, UNITY Dx and Anterion. In eye care, a biometer is a device that uses laser technology to take highly precise measurements of the eye's internal structures. It is most frequently used to help determine the exact power of the intraocular lens (IOL) needed before cataract removal.
Eligibility
Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Have healthy, clear corneas for the normal cohort;
* Have documented keratoconus for the keratoconus cohort;
* Have reported use of daily contact lens use for the contact lens cohort;
* Have documented dry eye, consisting of signs and symptoms for the dry eye cohort;
* Has had previous keratorefractive surgery for the post-refractive surgery cohort;
* Able to comprehend and sign the informed consent form.
Exclusion Criteria:
* Active ocular infection or inflammation;
* Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus);
* Any ocular disease and/or condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study result or may interfere significantly with the subject's participation in the study.
Primary outcome measure(s)
Regression-Based Axial Length (R-AL) — Day 1 Regression-based Axial Length (R-AL) is the distance from the anterior surface of the cornea to the retina at the back of the eye, measured along the visual axis. R-AL will be measured by the device and reported in microns.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.